Table 1.
Context-dependent mechanisms of the lactate-lactylation axis in kidney disease.
| Disease model | Implicated cell type/compartment | Lactate axis component & target site | Major phenotype | Evidence type | References |
|---|---|---|---|---|---|
| Sepsis (CLP) | HK-2 | Lactylation machinery: Fis1 K20 | Mitochondrial dysfunction (Injury) | Perturbation (in vivo/in vitro) | [67] |
| Sepsis (CLP) | HK-2 | Lactylation machinery: H3K18 and Ezrin K263 | Inflammation/apoptosis | Perturbation (in vivo/in vitro) | [65] |
| Sepsis (CLP) | Macrophages | Lactylation machinery: HMGB1 | NET formation | Perturbation (in vivo/in vitro) | [69] |
| I/R-AKI | HK-2 | Lactylation machinery: H3K18 | Enhanced glycolysis | Perturbation (in vivo/in vitro) | [70] |
| I/R-AKI | TEC | Lactylation machinery: c-Myc | TEC proliferation | Perturbation (in vivo/in vitro) | [64] |
| CDDP/MA-AKI | HK-2 | Lactylation machinery: ALDH2 K52 | Mitochondrial dysfunction (Injury) | Perturbation (in vivo/in vitro) | [71] |
| Lactate-AKI | HK-2 | Lactylation machinery: HMGB1 | NET formation | Perturbation (in vivo/in vitro) | [72] |
| DN (db/db) | HK-2/mTEC | Lactylation machinery: H3K14 | EMT | Perturbation (in vivo/in vitro) | [73] |
| DN (STZ) | MPC | Lactylation machinery: Histones | EMT of podocytes | Perturbation (in vivo/in vitro) | [74] |
| DN (db/db) | HK-2 | Lactylation machinery: ACSF2 K182 | Mitochondrial dysfunction | Associative (in vivo/in vitro) | [75] |
| DN (STZ) | mRTEC | Lactylation machinery: H3 | Fibrosis | Perturbation (in vivo/in vitro) | [76] |
| DN (STZ) | GEnCs | Lactylation machinery: H3K18 | Endomt/Fibrosis | Perturbation (in vivo/in vitro) | [77] |
| DN (STZ) | HK-2 | Lactylation machinery: TRIM65 K206 | Enhanced glycolysis | Perturbation (in vivo/in vitro) | [78] |
| DN (STZ) | HPCs | Lactylation machinery: LARS1 K970 | Inhibition of podocyte autophagy | Perturbation (in vivo/in vitro) | [79] |
| LN (PBMC immune reconstruction) | MC/HEK293 | Lactylation machinery: PBX1 K40 | Proliferation of MC | Perturbation (in vivo/in vitro) | [80] |
| UUO-CKD | HK-2 | Lactylation machinery: H4K12 | M2 polarization | Perturbation (in vivo/in vitro) | [66] |
| CDDP-CKD | BUMPT | Lactylation machinery: H3K18 | Fibrosis | Perturbation (in vivo/in vitro) | [81] |
CLP: Cecal Ligation and Puncture; HK-2: Human Kidney-2 cells; Fis1: Mitochondrial fission 1 protein; H3K18: Histone H3 lysine 18; Ezrin: Ezrin protein; HMGB1: High Mobility Group Box 1; NET: Neutrophil Extracellular Trap; I/R-AKI: Ischemia/Reperfusion-Induced Acute Kidney Injury; TEC: Tubular Epithelial Cells; c-Myc: Cellular Myelocytomatosis oncogene; CDDP/MA-AKI: Cisplatin/Mannitol-Induced Acute Kidney Injury; ALDH2: Aldehyde Dehydrogenase 2; Lactate-AKI: Lactate-Induced Acute Kidney Injury; DN: Diabetic Nephropathy; db/db: Diabetic (db/db) mouse model; mTEC: Mouse Tubular Epithelial Cells; H3K14: Histone H3 lysine 14; STZ: Streptozotocin; MPC: Mouse Podocyte Cells; ACSF2: Acyl-CoA Synthetase Family Member 2; mRTEC: Mouse Renal Tubular Epithelial Cells; H3: Histone H3; GEnCs: Glomerular Endothelial Cells; TRIM65: Tripartite Motif Containing 65; HPCs: Human Podocyte Cells; LARS1: Leucyl-tRNA Synthetase 1; LN: Lupus Nephritis; PBMC: Peripheral Blood Mononuclear Cells; MC: Mesangial Cells; HEK293: Human Embryonic Kidney 293 cells; PBX1: Pre-B-Cell Leukemia Homeobox 1; UUO-CKD: Unilateral Ureteral Obstruction-Induced Chronic Kidney Disease; M2: M2 macrophage phenotype; H4K12: Histone H4 lysine 12; CDDP-CKD: Cisplatin-Induced Chronic Kidney Disease; BUMPT: Boston University Mouse Proximal Tubule cell line.